human papillomavirus 16 e7 peptide
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1995 (NCT00019110)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- human papillomavirus 16 e7 peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003977 | Phase 1 | Nov 1, 1999 | National Cancer Institute (NCI), Tufts University |
| NCT00002916 | Phase 2 | Nov 1, 1996 | European Organisation for Research and Treatment of Cancer, University of Dundee |
| NCT00019110 | Phase 1 | Nov 1, 1995 | National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 1995 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1996 |
| Tufts University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of Dundee | Academic/Hospital | 1 | 0 | 1 | 1996 |
4 organizations
Page 1 / 1